Inhibition of growth of transformed cells and tumors by an endogenous acceptor of galactosyltransferase

D. K. Podolsky, M. M. Weiser, K. J. Isselbacher

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A galactosyltransferase glycopeptide acceptor purified from human malignant effusions was tested for its effects on cell growth in vitro and in vivo. Addition of the glycopeptide to the media of cells growing in tissue culture caused a significant inhibition of attachment and growth of transformed cells but had minimal effect on nontransformed cells. Transformed hamster cells (BHKpy, BHKpygiv, NILpy) and human malignant cells (BT-20 human breast and pancreatic carcinoma cells) were killed by the addition of as little as 0.5 μg of acceptor (per ml of medium), while nontransformed counterparts did not show a significant change in growth or morphology. In vivo studies showed that the acceptor inhibited development and progression of tumors in hamsters inoculated with tumorigenic BHKpy cells. Growth of tumors was inhibited 69-94% in animals given 20 μg of acceptor subcutaneously and 39-67% when acceptor was given intraperitoneally at the time of tumor cell inoculation. Administration of the acceptor after the development of a palpable tumor (~0.5 cm) caused a 60-85% reduction in growth rate and, in some cases, actual reduction in size and disappearance of palpable tumor. These studies demonstrate that a galactosyltransferase glycopeptide acceptor purified from human malignant effusions produces selective inhibition of transformed cell growth in animal and tissue culture systems.

Original languageEnglish (US)
Pages (from-to)4426-4430
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume75
Issue number9
StatePublished - 1978

Fingerprint

Growth
Neoplasms
Glycopeptides
Cricetinae
galactosyltransferase acceptor
Breast Neoplasms

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Inhibition of growth of transformed cells and tumors by an endogenous acceptor of galactosyltransferase. / Podolsky, D. K.; Weiser, M. M.; Isselbacher, K. J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 75, No. 9, 1978, p. 4426-4430.

Research output: Contribution to journalArticle

@article{2b44756da4b647a38b3578e08ee78ac8,
title = "Inhibition of growth of transformed cells and tumors by an endogenous acceptor of galactosyltransferase",
abstract = "A galactosyltransferase glycopeptide acceptor purified from human malignant effusions was tested for its effects on cell growth in vitro and in vivo. Addition of the glycopeptide to the media of cells growing in tissue culture caused a significant inhibition of attachment and growth of transformed cells but had minimal effect on nontransformed cells. Transformed hamster cells (BHKpy, BHKpygiv, NILpy) and human malignant cells (BT-20 human breast and pancreatic carcinoma cells) were killed by the addition of as little as 0.5 μg of acceptor (per ml of medium), while nontransformed counterparts did not show a significant change in growth or morphology. In vivo studies showed that the acceptor inhibited development and progression of tumors in hamsters inoculated with tumorigenic BHKpy cells. Growth of tumors was inhibited 69-94{\%} in animals given 20 μg of acceptor subcutaneously and 39-67{\%} when acceptor was given intraperitoneally at the time of tumor cell inoculation. Administration of the acceptor after the development of a palpable tumor (~0.5 cm) caused a 60-85{\%} reduction in growth rate and, in some cases, actual reduction in size and disappearance of palpable tumor. These studies demonstrate that a galactosyltransferase glycopeptide acceptor purified from human malignant effusions produces selective inhibition of transformed cell growth in animal and tissue culture systems.",
author = "Podolsky, {D. K.} and Weiser, {M. M.} and Isselbacher, {K. J.}",
year = "1978",
language = "English (US)",
volume = "75",
pages = "4426--4430",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "9",

}

TY - JOUR

T1 - Inhibition of growth of transformed cells and tumors by an endogenous acceptor of galactosyltransferase

AU - Podolsky, D. K.

AU - Weiser, M. M.

AU - Isselbacher, K. J.

PY - 1978

Y1 - 1978

N2 - A galactosyltransferase glycopeptide acceptor purified from human malignant effusions was tested for its effects on cell growth in vitro and in vivo. Addition of the glycopeptide to the media of cells growing in tissue culture caused a significant inhibition of attachment and growth of transformed cells but had minimal effect on nontransformed cells. Transformed hamster cells (BHKpy, BHKpygiv, NILpy) and human malignant cells (BT-20 human breast and pancreatic carcinoma cells) were killed by the addition of as little as 0.5 μg of acceptor (per ml of medium), while nontransformed counterparts did not show a significant change in growth or morphology. In vivo studies showed that the acceptor inhibited development and progression of tumors in hamsters inoculated with tumorigenic BHKpy cells. Growth of tumors was inhibited 69-94% in animals given 20 μg of acceptor subcutaneously and 39-67% when acceptor was given intraperitoneally at the time of tumor cell inoculation. Administration of the acceptor after the development of a palpable tumor (~0.5 cm) caused a 60-85% reduction in growth rate and, in some cases, actual reduction in size and disappearance of palpable tumor. These studies demonstrate that a galactosyltransferase glycopeptide acceptor purified from human malignant effusions produces selective inhibition of transformed cell growth in animal and tissue culture systems.

AB - A galactosyltransferase glycopeptide acceptor purified from human malignant effusions was tested for its effects on cell growth in vitro and in vivo. Addition of the glycopeptide to the media of cells growing in tissue culture caused a significant inhibition of attachment and growth of transformed cells but had minimal effect on nontransformed cells. Transformed hamster cells (BHKpy, BHKpygiv, NILpy) and human malignant cells (BT-20 human breast and pancreatic carcinoma cells) were killed by the addition of as little as 0.5 μg of acceptor (per ml of medium), while nontransformed counterparts did not show a significant change in growth or morphology. In vivo studies showed that the acceptor inhibited development and progression of tumors in hamsters inoculated with tumorigenic BHKpy cells. Growth of tumors was inhibited 69-94% in animals given 20 μg of acceptor subcutaneously and 39-67% when acceptor was given intraperitoneally at the time of tumor cell inoculation. Administration of the acceptor after the development of a palpable tumor (~0.5 cm) caused a 60-85% reduction in growth rate and, in some cases, actual reduction in size and disappearance of palpable tumor. These studies demonstrate that a galactosyltransferase glycopeptide acceptor purified from human malignant effusions produces selective inhibition of transformed cell growth in animal and tissue culture systems.

UR - http://www.scopus.com/inward/record.url?scp=0018116970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018116970&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 4426

EP - 4430

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -